Histopathology, cell proliferation indices and clinical outcome in 304 patients with mantle cell lymphoma (MCL):: a clinicopathological study from the European MCL Network

被引:233
|
作者
Tiemann, M
Schrader, C
Klapper, W
Dreyling, MH
Campo, E
Norton, A
Berger, F
Kluin, P
Ott, G
Pileri, S
Pedrinis, E
Feller, AC
Merz, H
Janssen, D
Hansmann, ML
van Krieken, H
Möller, P
Stein, H
Unterhalt, M
Hiddemann, W
Parwaresch, R
机构
[1] Univ Hosp Schleswig Holstein, Dept Haematol, D-24116 Kiel, Germany
[2] Univ Hosp Schleswig Holstein, Dept Haematopathol, D-24116 Kiel, Germany
[3] Univ Hosp Schleswig Holstein, Lymph Node Registry, D-24116 Kiel, Germany
[4] Univ Munich, Div Med 3, Munich, Germany
[5] Dept Haematopathol, Barcelona, Spain
[6] Barts & London NHS Trust, Dept Histopathol, London, England
[7] Ctr Hosp Lyon Sud, Dept Pathol, F-69310 Pierre Benite, France
[8] Leiden Univ, Dept Pathol, Leiden, Netherlands
[9] Univ Wurzburg, Dept Pathol, D-8700 Wurzburg, Germany
[10] Univ Bologna, Bologna, Italy
[11] Dept Pathol, Locarno, Switzerland
[12] Univ Hosp Schleswig Holstein, Dept Pathol, Lubeck, Germany
[13] Goethe Univ Frankfurt, Dept Pathol, D-6000 Frankfurt, Germany
[14] Univ Nijmegen, Dept Pathol, Nijmegen, Netherlands
[15] Univ Ulm, Dept Pathol, Ulm, Germany
[16] Univ Berlin, Dept Pathol, Berlin, Germany
关键词
mantle cell lymphoma; cytology; growth pattern; Ki-67; index; mitotic index;
D O I
10.1111/j.1365-2141.2005.05716.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Mantle cell lymphoma (MCL) is a distinct lymphoma subtype with a particularly poor clinical outcome. The clinical relevance of the morphological characteristics of these tumours remains uncertain. The European MCL Network reviewed 304 cases of MCL to determine the prognostic significance of histopathological characteristics. Cytomorphological subtypes, growth pattern and markers of proliferation (mitotic and Ki-67 indices) were analysed. In addition to the known cytological subtypes, classical (87.5%), small cell (3.6%), pleomorphic (5.9%) and blastic (2.6%), we identified new pleomorphic subgroups with mixtures of cells (classical + pleomorphic type; 1.6%) or transitions (classical/pleomorphic type; 1.6%), which, however, did not differ significantly in overall survival time. Exactly 80.5% of cases displayed a diffuse growth pattern, whereas 19.5% of cases had a nodular growth pattern, which was associated with a slightly more favourable prognosis. A high proliferation rate (mitotic or Ki-67 indices) was associated with shorter overall survival. Cut-off levels were defined that allowed three subgroups with different proliferation rates to be discriminated, which showed significantly different clinical outcomes (P < 0.0001). Based on this large clinicopathological study of prospective clinical trials, multivariate analysis confirmed the central prognostic role of cell proliferation and its superiority to all other histomorphological and clinical criteria.
引用
收藏
页码:29 / 38
页数:10
相关论文
共 50 条
  • [21] "In Situ" Mantle Cell Lymphoma (MCL), an Incidental Finding with an Indolent Clinical Course
    Carvajal, A.
    Sua, L.
    Silva, N.
    Pittaluga, S.
    Royo, C.
    Sargent, R. L.
    Climent, F.
    Jacobs, S. A.
    Delabie, J.
    Naresh, K.
    Bagg, A.
    Harris, N. L.
    Swerdlow, S. H.
    Jaffe, E. S.
    Campo, E.
    LABORATORY INVESTIGATION, 2011, 91 : 289A - 289A
  • [22] The clinical significance of detection of gastrointestinal (GI) involvement in mantle cell lymphoma (MCL)
    Romaguera, JE
    Hagemeister, FB
    Fayad, LE
    Rodriguez, MA
    Medeiros, LJ
    Pro, B
    Younes, A
    Sarris, AH
    Dang, NH
    Samaniego, F
    Brown, HM
    Gagneja, HK
    Cabanillas, F
    BLOOD, 2002, 100 (11) : 281B - 281B
  • [23] High Dose Sequential Chemotherapy (HDS) improves the outcome of patients with disseminated Mantle Cell Lymphoma (MCL)
    Cortelazzo, S
    Rambaldi, A
    Rossi, A
    Oldani, E
    Conconi, A
    Tarella, C
    Benedetti, F
    Devizzi, L
    Martelli, M
    Zinzani, PL
    Gianni, AM
    Barbui, T
    BONE MARROW TRANSPLANTATION, 2001, 27 : S259 - S259
  • [24] Treatment of Older Patients With Mantle Cell Lymphoma (MCL): Long-Term Follow-Up of the Randomized European MCL Elderly Trial
    Kluin-Nelemans, Hanneke C.
    Hoster, Eva
    Hermine, Olivier
    Walewski, Jan
    Geisler, Christian H.
    Trneny, Marek
    Stilgenbauer, Stephan
    Kaiser, Florian
    Doorduijn, Jeanette K.
    Salles, Gilles
    Szymczyk, Michal
    Tilly, Herve
    Kanz, Lothar
    Schmidt, Christian
    Feugier, Pierre
    Thieblemont, Catherine
    Zijlstra, Josee M.
    Ribrag, Vincent
    Klapper, Wolfram
    Pott, Christiane
    Unterhalt, Michael
    Dreyling, Martin H.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (03) : 248 - +
  • [25] Improved outcome of patients with mantle cell lymphoma (MCL) in first remission (CRI) after hematopoietic stem cell transplantation
    Kassim, A.
    Jagasia, M.
    Dixon, S.
    Chinratanalab, W.
    Morgan, D.
    Ruffner, K.
    Greer, J.
    Stein, R.
    Engelhardt, B.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2007, 13 (02) : 55 - 55
  • [26] LARGE-CELL VARIANTS OF MANTLE CELL LYMPHOMA (MCL) - CYTOLOGIC CHARACTERISTICS PREDICT POOR OUTCOME
    ZOLDAN, MC
    INGHIRAMI, G
    MASUDA, Y
    VANDEKERCKHOVE, F
    FRIZZERA, G
    LABORATORY INVESTIGATION, 1995, 72 (01) : A124 - A124
  • [27] Healthcare resource utilization (HRU) in treated mantle cell lymphoma (MCL) patients
    Kozma, Chris M.
    Slaton, Terra
    Ellis, Lorie
    McKenzie, R. S.
    CANCER RESEARCH, 2014, 74 (19)
  • [28] Correction: Expression patterns and prognostic potential of circular RNAs in mantle cell lymphoma: a study of younger patients from the MCL2 and MCL3 clinical trials
    Mette Dahl
    Simon Husby
    Christian W. Eskelund
    Søren Besenbacher
    Søren Fjelstrup
    Christophe Côme
    Sara Ek
    Arne Kolstad
    Riikka Räty
    Mats Jerkeman
    Christian H. Geisler
    Jørgen Kjems
    Lasse S. Kristensen
    Kirsten Grønbæk
    Leukemia, 2022, 36 : 1198 - 1198
  • [29] Efficacy of venetoclax in high risk relapsed mantle cell lymphoma (MCL) - outcomes and mutation profile from venetoclax resistant MCL patients
    Jain, Preetesh
    Zhao, Shuangtao
    Kanagal-Shamanna, Rashmi
    Navsaria, Lucy
    Ok, Chi Young
    Zhang, Shaojun
    Nomie, Krystle
    Han, Guangchun
    Hao, Dapeng
    Hill, Holly A.
    Jiang, Changying
    Yao, Yixin
    Nastoupil, Loretta
    Westin, Jason
    Fayad, Luis
    Nair, Ranjit
    Steiner, Raphel
    Ahmed, Sairah
    Samaniego, Felipe
    Iyer, Swaminathan P.
    Oriabure, Onyeka
    Chen, Wendy
    Song, Xingzhi
    Zhang, Jianhua
    Badillo, Maria
    Moghrabi, Omar
    Tang, Guilin
    Yin, C. Cameron
    Patel, Keyur
    Medeiros, Leonard Jeffrey
    Li, Shaoying
    Vega, Francisco
    Thirumurthi, Selvi
    Xu, Guofan
    Neelapu, Sattva
    Flowers, Christopher R.
    Romaguera, Jorge
    Fowler, Nathan
    Wang, Linghua
    Wang, Michael L.
    AMERICAN JOURNAL OF HEMATOLOGY, 2020, 95 (06) : 623 - 629
  • [30] Bystander vaccine therapy in mantle cell lymphoma (MCL): Phase II clinical results
    Shah, B. D.
    Tao, J.
    Sokol, L.
    Chervenick, P. A.
    Tomblyn, M. R.
    Pinilla-Ibarz, J.
    Moscinski, L.
    Antonia, S.
    Sotomayor, E. M.
    Dessureault, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)